

## Dosing Recommendations for Adult Patients with Drug-Susceptible Organisms

Drug	Normal Renal Function	Change in Frequency?	Creatinine Clearance <30 mL/min <sup>a</sup>
Isoniazid	300 mg once daily, or 900 mg 3 times weekly	No	N/A
Rifampin	600 mg once daily, or 600 mg 3 times weekly	No	N/A
Rifabutin	300 mg once daily	No	N/A
Rifapentine	10-20 mg/kg <i>once weekly</i>	No	N/A
Pyrazinamide	40-55 kg: 1000 mg daily <sup>b</sup> 56-75 kg: 1500 mg daily <sup>b</sup> 76-90 kg: 2000 mg daily <sup>b</sup>	Yes	25-35 mg/kg/dose 3 times weekly
Ethambutol	40-55 kg: 800 mg daily <sup>b</sup> 56-75 kg: 1200 mg daily <sup>b</sup> 76-90 kg: 1600 mg daily <sup>b</sup>	Yes	20-25 mg/kg/dose 3 times weekly
Levofloxacin	500-1000 mg once daily	Yes	750-1000 mg/dose 3 times weekly
Moxifloxacin	400 mg once daily	No	400 mg once daily

<sup>a</sup>Including adult patients receiving hemodialysis

<sup>b</sup>Based on estimated lean body weight. Optimal doses for obese patients are not established.

**Please note:** Standard doses are given unless there is intolerance; there should be careful monitoring of neurotoxicity; the medications should be given after hemodialysis on the day of hemodialysis; and monitoring of serum drug concentrations should be considered.



## Tuberculosis Treatment Guidelines

Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms

Dosing Recommendations for Adult Patients with Drug-Susceptible Organisms


**Reference: Official American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases • 2016**

*This publication was supported by the Grant or Cooperative Agreement Number NUS2PS910161-01 funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.*

2303 Southeast Military Drive • San Antonio, Texas 78223

1-800-TEX-LUNG • [www.heartlandntbc.org](http://www.heartlandntbc.org)

## Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms

Regimen	<i>Intensive Phase</i>		<i>Continuation Phase</i>		Range of Total Doses	Comments <sup>c,d</sup>	Regimen Effectiveness Greater  Lesser
	Drug <sup>a</sup>	Interval and Dose <sup>b</sup> ( <i>Minimum Duration</i> )	Drugs	Interval/Dose <sup>b,c</sup> ( <i>Minimum Duration</i> )			
1	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	7 d/wk for 126 doses (18 wk), or 5 d/wk for 90 doses (18 wk)	182-130	This is the preferred regimen for patients with newly diagnosed pulmonary tuberculosis.	
2	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	110-94	Preferred alternative regimen in situations in which more frequent DOT during continuation phase is difficult to achieve.	
3	INH RIF PZA EMB	3 times weekly for 24 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	78	Use regimen with caution in patients with HIV and/or cavitory disease. Missed doses can lead to treatment failure, relapse, and acquired drug resistance.	
4	INH RIF PZA EMB	7 d/wk for 14 doses then twice weekly for 12 doses	INH RIF	Twice weekly for 36 doses (18 wk)	62	Do not use twice-weekly regimens in HIV-infected patients or patients with smear-positive and/or cavitory disease. If doses are missed, then therapy is equivalent to once weekly, which is inferior.	

**a** Other combinations may be appropriate in certain circumstances; **b** When DOT is used, drugs may be given 5 days per week and the necessary number of doses adjusted accordingly. Although there are no studies that compare 5 with 7 daily doses, extensive experience indicates this would be an effective practice. DOT should be used when drugs are administered <7 days per week; **c** Based on expert opinion, patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-week) continuation phase; **d** Pyridoxine (vitamin B6), 25–50 mg/day, is given with INH to all persons at risk of neuropathy (eg, pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic renal failure; or patients with advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day; **e** See [426]. Alternatively, some US tuberculosis control programs have administered intensive-phase regimens 5 days per week for 15 doses (3 weeks), then twice weekly for 12 doses.

*DOT*-directly observed therapy; *EMB*-ethambutol; *INH*-isoniazid; *PZA*-pyrazinamide; *RIF*-rifampin